Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave, Labcorp To Co-Develop Companion Dx for Arca Discovery's Heart Failure Drug

NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it will collaborate with Laboratory Corporation of America to develop a diagnostic that may be used in conjunction with a heart failure drug that is being developed by Arca Discovery. 
The diagnostic is intended to help physicians determine use of the drug bucindolol, a beta blocker that Third Wave said could be "the first genetically targeted cardiovascular drug."
The test will be developed in tandem with the drug's approval process, the company added.
Bucindolol has shown "extensive" efficacy and safety in Phase III trials, Third Wave said, noting that Arca plans to use genetic data to target patients most likely to respond to the drug when it seeks FDA approval in 2008.
Labcorp acquired the rights to develop and commercialize the companion diagnostic for the Arca drug in February.
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.